Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2015 1
2016 1
2017 1
2018 1
2019 1
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Among authors: cirauqui cirauqui b. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
SEOM clinical guidelines for the treatment of head and neck cancer (2017).
Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui Cirauqui B, Escobar Y, Lambea Sorrosal JJ, Pastor Borgoñón M, Rueda A, Cruz Hernández JJ. Iglesias Docampo LC, et al. Among authors: cirauqui cirauqui b. Clin Transl Oncol. 2018 Jan;20(1):75-83. doi: 10.1007/s12094-017-1776-1. Epub 2017 Nov 20. Clin Transl Oncol. 2018. PMID: 29159792 Free PMC article.
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Martínez-Trufero J, et al. Among authors: cirauqui cirauqui b. Clin Transl Oncol. 2021 Aug;23(8):1666-1677. doi: 10.1007/s12094-021-02567-z. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876416 Clinical Trial.
[Dose intensity received in breast cancer treatment with chemotherapy].
Quiñones Ribas C, Pontón Sivillá JL, Margelí Vila M, Cirauqui Cirauqui B, Modamio Charles P, Mariño Hernández EL, Bonafont Pujol X. Quiñones Ribas C, et al. Among authors: cirauqui cirauqui b. Farm Hosp. 2007 Sep-Oct;31(5):270-5. doi: 10.1016/s1130-6343(07)75390-4. Farm Hosp. 2007. PMID: 18052629 Spanish.
Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.
Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, Luna-Tomás MÁ, Castellà-Fernández EM, Mariscal-Martínez A, Margelí-Vila M. Quiroga-García V, et al. Among authors: cirauqui cirauqui b. Breast Care (Basel). 2015 Jul;10(3):179-83. doi: 10.1159/000382112. Epub 2015 May 22. Breast Care (Basel). 2015. PMID: 26648829 Free PMC article.